The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
The influence of the duration of exposure to the halogenated pyrimidines iododeoxyuridine (IdUrd) and bromodeoxyuridine (BrdUrd) on incorporation into DNA and the resulting radiosensitization was studied in cultured human colon cancer cells. Cells were incubated with either 10 microM BrdUrd or IdUrd for periods up to 7 days. They were also assessed for up to 4 days after removal of drug from the medium. Replacement of thymidine by fraudulent bases was measured using a sensitive gas chromatographic, mass spectrometric (GC/MS) assay. Incorporation of BrdUrd and IdUrd plateaued at 35% and 30%, respectively, after 4 days of exposure. Prolonging the time of exposure to 7 days increased cytotoxicity without affecting either incorporation or radiosensitization. Incorporation remained constant for 1-2 days after removal of drug from the medium. Radiosensitization was linearly related to incorporation throughout the range of conditions assessed. These data suggest that it may be possible to develop a predictive assay for radiosensitization based on measurements of halogenated pyrimidine incorporation in a tumor biopsy specimen. They also suggest that a clinical approach based on repeated short exposures to halogenated pyrimidines may present certain advantages over the current practice of prolonged continuous exposure. A Phase I/II trial using IdUrd and external beam irradiation for the treatment of patients with poor prognosis soft tissue sarcomas has been initiated based on this concept.
Lawrence
T S
TS
Dept. of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109.
Davis
M A
MA
Maybaum
J
J
Stetson
P L
PL
Ensminger
W D
WD
D001973:Bromodeoxyuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004273:DNA, Neoplasm / Q000378:metabolism*; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D004273:DNA, Neoplasm; D011838:Radiation-Sensitizing Agents; D001973:Bromodeoxyuridine; D007065:Idoxuridine